Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Acasti Pharma reported $-0.21 in EPS Earnings Per Share for its fiscal quarter ending in June of 2025. Data for Acasti Pharma | ACST - EPS Earnings Per Share including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Acasti Pharma reported $9.94 in PE Price to Earnings for its fiscal quarter ending in March of 2021. Data for Acasti Pharma | ACST - PE Price to Earnings including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Acasti Pharma reported $-4.76M in Sales Revenues for its fiscal quarter ending in December of 2024. Data for Acasti Pharma | ACST - Sales Revenues including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Acasti Pharma reported $-3.09M in Operating Profit for its fiscal quarter ending in June of 2025. Data for Acasti Pharma | ACST - Operating Profit including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterThe revenue of Grace Therapeutics, Inc. with headquarters in the United States amounted to ************ U.S. dollars in 2021. The reported fiscal year ends on March 31.Compared to 2020, this marks an increase of approximately ************* U.S. dollars. The trend from 2020 to 2021 shows, furthermore, that this increase happened continuously.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Acasti Pharma stock price, live market quote, shares value, historical data, intraday chart, earnings per share and news.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Acasti Pharma reported $32 in Employees for its fiscal year ending in March of 2021. Data for Acasti Pharma | ACST - Employees Total Number including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Acasti Pharma reported $66.58M in Assets for its fiscal quarter ending in September of 2025. Data for Acasti Pharma | ACST - Assets including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Acasti Pharma reported $-0.36 in Interest Income for its fiscal quarter ending in December of 2024. Data for Acasti Pharma | ACST - Interest Income including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Acasti Pharma reported $32.1M in Market Capitalization this December of 2025, considering the latest stock price and the number of outstanding shares.Data for Acasti Pharma | ACST - Market Capitalization including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Acasti Pharma reported $0 in Loan Capital for its fiscal quarter ending in December of 2024. Data for Acasti Pharma | ACST - Loan Capital including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Acasti Pharma reported $17.3M in Current Assets for its fiscal quarter ending in September of 2025. Data for Acasti Pharma | ACST - Current Assets including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Acasti Pharma reported $0 in Debt for its fiscal quarter ending in September of 2024. Data for Acasti Pharma | ACST - Debt including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Acasti Pharma reported $1.24M in Current Liabilities for its fiscal quarter ending in September of 2025. Data for Acasti Pharma | ACST - Current Liabilities including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Acasti Pharma reported $1.34M in Trade Creditors for its fiscal quarter ending in June of 2025. Data for Acasti Pharma | ACST - Trade Creditors including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Acasti Pharma reported $62.82M in Equity Capital and Reserves for its fiscal quarter ending in September of 2025. Data for Acasti Pharma | ACST - Equity Capital And Reserves including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Acasti Pharma reported $2.14M in Selling and Administration Expenses for its fiscal quarter ending in June of 2025. Data for Acasti Pharma | ACST - Selling And Administration Expenses including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Acasti Pharma reported $1.43M in Interest Expense on Debt for its fiscal quarter ending in September of 2020. Data for Acasti Pharma | ACST - Interest Expense On Debt including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Acasti Pharma reported $-3.36M in Pre-Tax Profit for its fiscal quarter ending in June of 2025. Data for Acasti Pharma | ACST - Pre Tax Profit including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Acasti Pharma reported $1000 in Ordinary Share Capital for its fiscal quarter ending in December of 2024. Data for Acasti Pharma | ACST - Ordinary Share Capital including historical, tables and charts were last updated by Trading Economics this last December in 2025.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Acasti Pharma reported $-0.21 in EPS Earnings Per Share for its fiscal quarter ending in June of 2025. Data for Acasti Pharma | ACST - EPS Earnings Per Share including historical, tables and charts were last updated by Trading Economics this last December in 2025.